Connect with us

Technology

Flow Cytometer Market to Expand by USD 8.17 Billion (2024-2028), Rising R&D Investments Drive Growth, Report on AI’s Impact on Market Trends – Technavio

Published

on

NEW YORK, Nov. 26, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global flow cytometer market size is estimated to grow by USD 8.17 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of about 15.2% during the forecast period. Increasing expenditure on r and d is driving market growth, with a trend towards increasing level of process automation. However, high cost of instruments poses a challenge.Key market players include Abbott Laboratories, Agilent Technologies Inc., Amphasys AG, Apogee Flow Systems Ltd., Becton Dickinson and Co., Bio Rad Laboratories Inc., Cytek Biosciences Inc., Danaher Corp., DiaSorin SpA, Enzo Biochem Inc., Miltenyi Biotec B.V. And Co. KG, Shenzhen Mindray BioMedical Electronics Co. Ltd, OLS OMNI Life Science GmbH and Co. KG, On-Chip Biotechnologies Co. Ltd., Sartorius AG, Sony Group Corp., Stratedigm Inc., Sysmex Corp., Thermo Fisher Scientific Inc., and Union Biometrica Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Flow Cytometer Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 – 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 15.2%

Market growth 2024-2028

USD 8170.7 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

12.86

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 32%

Key countries

US, China, UK, Germany, and Canada

Key companies profiled

Abbott Laboratories, Agilent Technologies Inc., Amphasys AG, Apogee Flow Systems Ltd., Becton Dickinson and Co., Bio Rad Laboratories Inc., Cytek Biosciences Inc., Danaher Corp., DiaSorin SpA, Enzo Biochem Inc., Miltenyi Biotec B.V. And Co. KG, Shenzhen Mindray BioMedical Electronics Co. Ltd, OLS OMNI Life Science GmbH and Co. KG, On-Chip Biotechnologies Co. Ltd., Sartorius AG, Sony Group Corp., Stratedigm Inc., Sysmex Corp., Thermo Fisher Scientific Inc., and Union Biometrica Inc.

Market Driver

The Flow Cytometer Market is experiencing significant growth due to the increasing demand for multiparametric data analysis in various industries. Stem cell cultures and fluorescent-labeled antibodies are key applications driving market expansion. Flow cytometry is used extensively in the research and diagnosis of diseases such as cancer, HIV, and autoimmune disorders. FlowMetric Life Sciences, innovators in flow cytometry, provide instruments, software, and flow cytometry services for drug discovery and cell line development. Flow cytometry techniques like Western blotting, immunohistochemistry, and microscopy complement the analysis. Accessories like fluorochrome combinations, liquid handling robotics, and bead-based assays expand the capabilities of flow cytometry. The market caters to biotechnology, life science, and biopharmaceutical research activities, offering point-of-care diagnostics for tuberculosis, sexually transmitted diseases, and other infectious diseases. Digital signal processing enhances data analysis solutions, while cellular diagnostics and immunodeficiency disorders are other major applications. Flow cytometry instruments include microfluidic flow cytometry and PCR, and antibody-based testing is a significant trend. 

Flow cytometry, a laboratory technique used for analyzing and sorting cells, has seen significant advancements in automation over the past few decades. Manual sample preparation and loading have been replaced with instruments that automate these processes. These devices feature digital interfaces and store processed information, reducing the need for human intervention. Integration with other devices and processes increases flexibility, enables continuous sample flow, and decreases processing time and supervision. Modern laboratory equipment can be integrated into a digital ecosystem, ensuring a seamless transition between processes. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

Flow cytometry is a crucial technology in life sciences and biotechnology industries for analyzing cells. It allows for the measurement of multiple parameters, including the use of fluorescent-labeled antibodies and compounds, on single cells. However, handling multiparametric data can be challenging. Stem cell cultures also pose unique difficulties. Flow cytometers, instruments, accessories, and software are essential tools for this technique. In cancer, HIV, and other diseases like leukemia and lymphoma, flow cytometry plays a significant role in diagnosis and drug discovery services. Flow cytometry innovators and contract service providers offer flow cytometry analysis for immune cells, cell line development, and cellular diagnostics. Parameters like digital signal processing and fluorochrome combinations enhance the technology’s capabilities. FlowMetric Life Sciences, liquid handling robotics, and microfluidic flow cytometry are recent advancements. Applications include clinical testing labs, PCR, antibody-based testing, and point-of-care diagnostics for diseases like tuberculosis and sexually transmitted diseases.The flow cytometer market is experiencing significant growth due to the increasing demand for advanced analytical tools in drug discovery and development for infectious and chronic diseases. Flow cytometers are essential instruments in this process, offering precise and accurate data. However, the high cost of these instruments poses a challenge to market expansion. Prices range from USD100,200 to USD500,200 for a single unit, with additional expenses for reagents, markers, consumables, and accessories. This investment is justified by the valuable data generated, but it remains a significant consideration for research organizations and pharmaceutical companies.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This flow cytometer market report extensively covers market segmentation by

Product1.1 Reagents and consumables1.2 Instruments1.3 OthersEnd-user2.1 Pharmaceutical industry2.2 Health and diagnostic centers2.3 OthersGeography3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Reagents and consumables- The global flow cytometer market is driven by the essential role of reagents and consumables in various applications across clinical diagnostics, research, and biopharmaceutical industries. Reagents, including fluorescently labeled antibodies, viability dyes, and calibration beads, enhance cellular property detection and quantification. Innovation in reagent composition leads to more effective products for molecular and cellular biology studies. Thermo Fisher Scientific and Bio-Rad Laboratories are key vendors offering a wide range of assays, antibodies, and reagents for flow cytometry. The market growth is fueled by the increasing prevalence of chronic diseases, advancements in personalized medicine, and research activities in immunology and cancer biology. High-quality consumables ensure sample integrity and accurate flow cytometric analyses. Investments in new antibody and Deoxo-Fluor reagents will further drive demand.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

Flow cytometry is a powerful analytical technique used in various fields of life science, biotechnology, and biopharmaceutical research activities. This technique enables the analysis of multiparametric data from individual cells using fluorescent-labeled antibodies or compounds. Stem cell cultures are increasingly utilizing flow cytometry for characterization and sorting. Control parameters such as forward and side scatter are used to identify and exclude debris and aggregates. Data analysis solutions help researchers make sense of the complex data generated. Flow cytometry services offer expertise and equipment for those without access to their own instruments. Flow cytometry is used in the diagnosis and research of various diseases, including autoimmune disorders, infectious diseases like HIV/AIDS, and cancer, as well as immunodeficiency disorders. Techniques such as Western blotting, immunohistochemistry, microscopy, and PCR are often used in conjunction with flow cytometry. Microfluidic flow cytometry and antibody-based testing are emerging applications. Flow cytometer instruments continue to advance, offering increased sensitivity, speed, and multiplexing capabilities.

Market Research Overview

Flow cytometry is a powerful analytical technology used to measure and analyze the physical and chemical characteristics of cells, including their size, shape, and the presence of specific markers. This technique employs the use of flow cytometers, instruments that pass single cells in suspension through a laser beam, exciting fluorescent-labeled antibodies or compounds attached to the cells. Multiparametric data is generated, allowing for the simultaneous measurement of multiple parameters. Stem cell cultures and immune cells are common applications, with flow cytometry playing a crucial role in cancer, HIV, leukemia, lymphoma, autoimmune disorders, infectious diseases, and drug discovery services. Flow cytometry analysis is essential for cell line development, immunodeficiency disorders, and biotechnology research activities. Innovations in flow cytometry include microfluidic flow cytometry, digital signal processing, point-of-care diagnostics, and cell-based flow cytometry. Accessories, software, and bead-based assays are also integral components of the flow cytometry ecosystem. FlowMetric Life Sciences and other contract service providers offer flow cytometry services to researchers and clinical testing labs. Fluorochrome combinations, liquid handling robotics, and PCR are additional tools used in conjunction with flow cytometry for various applications, including drug development activities and antibody-based testing for diseases like tuberculosis and sexually transmitted diseases.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductReagents And ConsumablesInstrumentsOthersEnd-userPharmaceutical IndustryHealth And Diagnostic CentersOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/flow-cytometer-market-to-expand-by-usd-8-17-billion-2024-2028-rising-rd-investments-drive-growth-report-on-ais-impact-on-market-trends—technavio-302315806.html

SOURCE Technavio

Continue Reading

Technology

Howard Hughes Holdings Set to Join S&P SmallCap 600

Published

on

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 28. S&P 500 constituent CRH plc (NYSE: CRH) has acquired Arcosa in a deal that closed today, October 23.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name  

Action

Company Name

Ticker

GICS Sector

October 28, 2026

S&P SmallCap 600

Addition

Howard Hughes Holdings

HHH

Real Estate

October 28, 2026

S&P SmallCap 600

Deletion

Arcosa

ACA

Industrials

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

Media Inquiries
spdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/howard-hughes-holdings-set-to-join-sp-smallcap-600-302918511.html

SOURCE S&P Dow Jones Indices

Continue Reading

Technology

Chelsea FC announces multi-year sleeve partnership with Sokin, the business payments and FX platform

Published

on

By

Chelsea FC name fast-growing fintech platform as Principal Partner

LONDON, Oct. 23, 2026 /PRNewswire/ — Chelsea Football Club has today announced a multi-year partnership with Sokin, the embedded finance and payments company used by businesses worldwide. Sokin will be named a Principal Partner and Official Business Payments and FX Partner of Chelsea FC and Chelsea FC Women.

As a Principal Partner, Sokin will be represented on the sleeves of the Chelsea FC men’s, women’s and academy home, away, and third kits from the 2026/27 season.

The partnership brings together two ambitious London-headquartered organisations with worldwide reach – a club with millions of fans across the world and a fintech platform through which businesses move more than $11 billion a year. A club of Chelsea’s scale works in many currencies every day, with partners, competitions and supporters around the world, and needs a financial partner built to handle that.

Sokin gives finance teams business payments, multi-currency accounts, foreign exchange, checkout and treasury in one place, so they spend less time juggling banks and providers and keep more of what they move.

As Official Business Payments and FX Partner, Sokin will simplify how Chelsea FC sends, receives and manages money in the currencies the club operates in.

The Sokin logo will feature on the sleeve of the Chelsea shirt for the first time [when the men’s team host Tottenham Hotspur at Stamford Bridge on Saturday 24th October.]

Jason Gannon, President at Chelsea FC said:

“At Chelsea, we seek to partner with organisations that share our ambition and innovative mindset. Sokin’s expertise in business payments, and their focus on making both simpler for the businesses they serve, makes them a natural fit for the Club. We are pleased to welcome Sokin to the Chelsea family and look forward to working together in the years ahead.”

Vroon Modgill, CEO and founder at Sokin said:

“Chelsea plays on the biggest stage in world football, and its business runs in dozens of currencies. Sokin was built for that with regulated, multi-currency payments and foreign exchange for organisations that operate internationally. We’re proud to be the platform behind the business payments and FX of one of the most iconic teams in football. Sokin’s platform serves businesses in more than 170 countries. We’re thrilled to be partners for the season ahead. An organisation as sophisticated as Chelsea doesn’t leave its finances to chance.”

About Sokin

Sokin is the financial layer global business runs on. Businesses can transact, convert and hold money in 70+ currencies across 170+ countries. Some businesses use Sokin to manage global finance in-house. Others build it into their products to power financial experiences for their customers. Businesses move more than $9 billion a year on licenses Sokin holds in 36+ countries and infrastructure Sokin owns. Founded in 2019, Sokin has raised over $100 million from investors including Morgan Stanley Expansion Capital and Prysm Capital.

About Chelsea Football Club

Chelsea Football Club is one of the biggest, most successful football clubs globally and our men’s team are reigning world champions, having won the four-yearly FIFA Club World Cup in 2025. Our women’s team, Chelsea Women, are also multiple trophy winners.

Founded in 1905, Chelsea is London’s most central football club, based at the iconic 40,000-capacity Stamford Bridge stadium. Nicknamed the Blues, the club lifted the Champions League for the first time in 2012 and domestically has won the Premier League five times, the FA Cup eight times, the Football League Cup five times and the Football League Championship once, in 1955.

The Chelsea Women’s team have enjoyed a huge amount of success and in 2025 won the FA Women’s Super League for a sixth consecutive year and the eighth time overall. The Women’s FA Cup has been won on six occasions. We have also captured the FA Women’s League Cup four times as well as reaching the UEFA Women’s Champions League final in 2021. In two seasons, 2020/21 and 2024/25, a domestic treble of trophies was secured.

The Chelsea Foundation boasts one of the most extensive community initiatives in sport, helping to improve the lives of children and young people all over the world.

Media Contacts:

Taina Biggs
taina.biggs@sokin.com 

Nerissa Chesterfield
nerissa.chesterfield@chelseafc.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/chelsea-fc-announces-multi-year-sleeve-partnership-with-sokin-the-business-payments-and-fx-platform-302918466.html

Continue Reading

Technology

Amy Johnson Appointed President of GDIT

Published

on

By

RESTON, Va., Oct. 23, 2026 /PRNewswire/ — General Dynamics (NYSE:GD) announced today that Amy Johnson has been appointed as president of GDIT, effective November 3.

Johnson is a 27-year veteran of General Dynamics Mission Systems, where she held increasingly senior roles in engineering, engineering management and business leadership across cybersecurity, defense electronics, space and intelligence systems, most recently as vice president and general manager for Space, Cyber and Intelligence. She earned bachelor’s and master’s degrees in computer science and computer systems engineering. 

“Amy has a proven track record of leading teams to solve complex and highly technical challenges for our customers,” said Phebe Novakovic, CEO of General Dynamics. “I am confident that her dynamic leadership, operational rigor and deep commitment to our values and culture will deliver value to our customers, employees and shareholders.”

GDIT delivers digital modernization, cloud computing, artificial intelligence, cybersecurity and software development solutions to the U.S. federal government, defense, intelligence agencies and other customers. It is a business unit of General Dynamics, a global aerospace and defense company that offers a broad portfolio of products and services in business aviation; ship construction and repair; land combat vehicles, weapons systems and munitions; and technology products and services. General Dynamics employs more than 120,000 people worldwide and generated $52.6 billion in revenue in 2025. More information is available at gd.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/amy-johnson-appointed-president-of-gdit-302918411.html

SOURCE General Dynamics

Continue Reading

Trending